Clinical Scorecard: Comprehensive Risk Assessment for Stage I–III Cutaneous Melanoma Through 31-Gene Expression Profiling: Insights from a Single-Center Investigation
At a Glance
Category
Detail
Condition
cutaneous melanoma
Key Mechanisms
gene expression profiling (GEP) to predict risk of distant metastasis and melanoma-specific survival
Target Population
patients with invasive cutaneous melanoma (AJCC clinical stages I–III)
Care Setting
academic, tertiary surgical oncology clinic
Key Highlights
GEP serves as an independent predictor of survival outcomes.
SLNB is recommended for patients with T2–T4 lesions.
The 31-GEP assay may help identify low-risk patients who can avoid SLNB.
Integration of GEP testing into standard care remains controversial.
The study aims to validate the DecisionDx 31-GEP assay in a large, unselected cohort.
Guideline-Based Recommendations
Diagnosis
Consider SLNB for patients with T1b tumors and recommend for T2–T4 lesions.
Management
Patients with GEP Class 2A or 2B results should undergo whole body PET/CT surveillance every 6 months for 5 years.
Monitoring & Follow-up
Routine clinical follow-up as per NCCN guidelines.
Risks
Current guidelines may underestimate SLNB positivity risk for low-risk patients.
Patient & Prescribing Data
patients with invasive cutaneous melanoma (AJCC clinical stages I–III)
GEP results did not influence the decision to perform SLNB.
Clinical Best Practices
Utilize GEP for improved risk stratification in melanoma patients.
Consider patient demographics and tumor characteristics when discussing SLNB.
by Daniel B. Gehle, Philip W. Morgan, Emme M. Fitts, Nathaniel L. Hauser, Chelsea R. Olson, Andrew M. Fleming, Julia Pedo Freitas, Feng Liu-Smith, Simonne S. Nouer, Andrew J. Murphy, Martin D. Fleming
